Doximity, Inc. (DOCS)
| Market Cap | 4.80B -54.6% |
| Revenue (ttm) | 637.78M +15.9% |
| Net Income | 239.40M +18.9% |
| EPS | 1.19 +18.9% |
| Shares Out | 184.71M |
| PE Ratio | 21.84 |
| Forward PE | 16.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,075,563 |
| Open | 25.58 |
| Previous Close | 26.03 |
| Day's Range | 24.99 - 26.00 |
| 52-Week Range | 20.55 - 76.51 |
| Beta | 1.35 |
| Analysts | Buy |
| Price Target | 45.50 (+75.14%) |
| Earnings Date | May 13, 2026 |
About DOCS
Doximity, Inc. operates as a digital platform for medical professionals in the United States. Its platform provides its members with digital tools built for medicine, that enables its members to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The company primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, ... [Read more]
Financial Performance
In fiscal year 2025, Doximity's revenue was $570.40 million, an increase of 19.98% compared to the previous year's $475.42 million. Earnings were $223.19 million, an increase of 51.23%.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for DOCS stock is "Buy." The 12-month stock price target is $45.5, which is an increase of 75.14% from the latest price.
News
Doximity to Release Fiscal 2026 Fourth Quarter and Full Year Results on May 13, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter ...
Doximity sinks after OpenAI rolls out ChatGPT for Clinicians
Shares of Doximity (DOCS) are down 4%, or $1.02, to $23.23 in morning trading.
Truist downgrades Doximity on weakening revenue growth visibility
Truist downgraded Doximity (DOCS) to Hold from Buy with a price target of $29, down from $37. The firm has a taken a more cautious outlook on Doximity, saying its
Doximity downgraded to Hold from Buy at Truist
Truist downgraded Doximity (DOCS) to Hold from Buy with a $29 price target
Doximity announces resignation of CFO Anna Bryson, reaffirms Q4, FY guidance
In a regulatory filing, the company stated, “As previously disclosed by Doximity (DOCS) on February 5, 2026, Anna Bryson, the company’s Chief Financial Officer, had been on medical leave. On
Doximity price target lowered to $47 from $56 at BofA
BofA lowered the firm’s price target on Doximity (DOCS) to $47 from $56 and keeps a Buy rating on the shares. The firm’s sixteenth quarterly survey on pharma advertising had
Doximity price target lowered to $30 from $38 at KeyBanc
KeyBanc lowered the firm’s price target on Doximity (DOCS) to $30 from $38 and keeps an Overweight rating on the shares. Ahead of Q1 earnings, the firm believes the setup
Doximity downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst Elizabeth Anderson downgraded Doximity (DOCS) to In Line from Outperform with a price target of $25, down from $30. The firm cites its slower market growth forecasts
Doximity initiated with a Buy at Freedom Capital
Freedom Capital analyst Gene Mannheimer initiated coverage of Doximity (DOCS) with a Buy rating and $31 price target The firm views Doximity as “more than just a ‘LinkedIn for docs’,”
Doximity Study Finds Physicians Rapidly Adopting AI, But Accuracy Concerns Persist
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released a new report examining how physicians are adopting artificial i...
Doximity price target lowered to $33 from $40 at JPMorgan
JPMorgan lowered the firm’s price target on Doximity (DOCS) to $33 from $40 and keeps a Neutral rating on the shares.
Doximity price target raised to $42 from $40 at Piper Sandler
Piper Sandler raised the firm’s price target on Doximity (DOCS) to $42 from $40 and keeps an Overweight rating on the shares. The firm had the opportunity to demo Doximity’s
Halper Sadeh LLC Encourages Doximity Inc. Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your right...
Doximity upgraded to Buy from Hold at Canaccord
Canaccord upgraded Doximity (DOCS) to Buy from Hold with a price target of $34, down from $48. The post earnings selloff is an overreaction to short-term fears that will prove
Doximity price target lowered to $38 from $60 at KeyBanc
KeyBanc lowered the firm’s price target on Doximity (DOCS) to $38 from $60 and keeps an Overweight rating on the shares.
Doximity Earnings Call Transcript: Q3 2026
Q3 revenue grew 10% year-over-year to $185.1M, with a 60% adjusted EBITDA margin and strong engagement across workflow and AI products. Delayed pharma budgets and policy headwinds impacted Q4 outlook, but double-digit growth is expected by year-end as AI commercialization ramps.
Doximity Ranked #1 Best in KLAS Telehealth Video Platform for Fifth Consecutive Year
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, announced today that Doximity Dialer has been named the #1 Telehealth Video Co...
Doximity Announces Fiscal 2026 Third Quarter Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 third quarter ended December 31, 20...
Doximity to Release Fiscal 2026 Third Quarter Results on February 5, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal third quarter e...
HALPER SADEH LLC ENCOURAGES DOXIMITY INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inves...
Doximity Earnings Call Transcript: Q2 2026
Q2 revenue grew 23% year-over-year to $169M, with a 60% Adjusted EBITDA margin and strong free cash flow. Integrated AI-optimized programs and agency partnerships drove growth, while guidance for FY26 was raised amid continued investment in AI and robust client engagement.
Doximity Announces Fiscal 2026 Second Quarter Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 second quarter ended September 30, ...
Doximity to Release Fiscal 2026 Second Quarter Results on November 6, 2025
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ...
Doximity, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating potential legal claims on behalf of Doximity, Inc. (NYSE: DOCS) shareholders, concerning alleged misconduct by certain officers and di...